Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Transformative Chemistry - Innovative Products |
Driving next-gen Biosensing and Diagnostics

Stock Quote Today & Recent News Gemina Laboratories Ltd. C.GLAB

Alternate Symbol(s):  GLABF

Healthcare Diagnostics & Research
Gemina Laboratories Ltd. is a Canada-based biosensor and diagnostic company with a transformative, patented, proprietary chemistry that powers testing platforms for a range of pathogens that affect human health and wellness. The Company operates in the in vitro diagnostics (IVD) and human wellness monitoring market under the name Gemina Labs. Its development pipeline includes platforms for the... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

"We are now targeting similar licensing deals with strategic partners across the life sciences and medical device sectors to enable next generation diagnostics with our unique suite of proprietary technologies.”

Brian Firth, CEO

Current News (CSE:GLAB)

Gemina Laboratories Announces Private Placement

Accesswire 7 days ago

Gemina Laboratories Strategic Update

Accesswire July 10, 2024

Gemina Laboratories Commences Trading on the OTCQB Market in the United States

Accesswire June 20, 2024

Gemina Labs Announces Addition to its IP Portfolio

Accesswire April 9, 2024

Gemina Laboratories Sign First Strategic License Agreement

Accesswire April 2, 2024

Gemina Labs Strategic Update: Focusing on Respiratory Infections and Strategic Partnerships

Accesswire March 21, 2024
View More News ››

"One of the great privileges of my role is to be able to partner with exciting researchers at the forefront of their field. Our UBC partnership with Dr. Clifford is an outstanding example of industrial-academic collaboration and we're delighted with the research results that we've been able to achieve, which now form an important addition to Gemina's growing IP-engine"

Robert Greene, CTO

Opinion & Analysis (CSE:GLAB)

No current opinion is available.
View More Opinion ››

2024 will see Gemina focus on licensing, supporting license customers and expanding the licensable asset base. We will also commit resources to laying the foundations for additional revenue streams in future years.

Bullboard Posts (CSE:GLAB)

Be the first to post on this bullboard.

Connect with C.GLAB

Visit X Visit Linked In Visit Youtube

TECHNOLOGY CORPORATE PRESENTATION NEWS OVERVIEW PRODUCTS MANAGEMENT

Investor Presentation

View the Presentation

Investment Opportunity

Delivering transformative chemistries that will redefine the future of the $43B POC diagnostics industry

  • Patent Portfolio: 34 inventions backed by patent applications.
     
  • Cost-Saving Breakthrough: Dramatic reduction in antibody use, forecasting $3B industry savings.
     
  • First Commercial License (2024): Achieved landmark commercial license, enabling worldwide distribution of Gemina’s technology (100s of millions units/year).
     
  • Commercial Expansion: Negotiating several similar licenses
     

Gemina Laboratories - Antibody Savings on Lateral Flow Assay

more...

Contact Us